



Ropinirole, a dopamine agonist with high D₃ affinity, reduces proactive inhibition: A double-blind, placebo-controlled study in healthy adults

Vishal Rawji^{*}, Lorenzo Rocchi, Tom Foltynie, John C. Rothwell, Marjan Jahanshahi

Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, Queen Square, London, UK

ARTICLE INFO

Keywords:

Response inhibition
Proactive inhibition
Reactive inhibition
Drift-diffusion model
Dopamine
Dopamine agonist
Impulsivity

ABSTRACT

Response inhibition describes the cognitive processes mediating the suppression of unwanted actions. A network involving the basal ganglia mediates two forms of response inhibition: reactive and proactive inhibition. Reactive inhibition serves to abruptly stop motor activity, whereas proactive inhibition is goal-orientated and results in slowing of motor activity in anticipation of stopping. Due to its impairment in several psychiatric disorders, the neurochemistry of response inhibition has become of recent interest. Dopamine has been posed as a candidate mediator of response inhibition due to its role in functioning of the basal ganglia and the observation that patients with Parkinson's disease on dopamine agonists develop impulse control disorders. Although the effects of dopamine on reactive inhibition have been studied, substantial literature on the role of dopamine on proactive inhibition is lacking. To fill this gap, we devised a double-blind, placebo-controlled study of 1 mg ropinirole (a dopamine agonist) on response inhibition in healthy volunteers. We found that whilst reactive inhibition was unchanged, proactive inhibition was impaired when participants were on ropinirole relative to when on placebo. To investigate how ropinirole mediated this effect on proactive inhibition, we used hierarchical drift-diffusion modelling. We found that ropinirole impaired the ability to raise the decision threshold when proactive inhibition was called upon. Our results provide novel evidence that an acute dose of ropinirole selectively reduces proactive inhibition in healthy participants. These results may help explain how ropinirole induces impulse control disorders in susceptible patients with Parkinson's disease.

1. Introduction

Response inhibition describes the cognitive processes involved in the suppression of unwanted thoughts and action (Jahanshahi et al., 2015). It can be divided into reactive and proactive inhibition, whereby reactive inhibition is called upon in response to sudden sensory cues and serves to abruptly stop motor activity, whereas proactive inhibition is goal-orientated and results in slowing of motor activity in anticipation of stopping. A breakdown in response inhibition is a feature of several psychiatric disorders such as schizophrenia (Bellgrove et al., 2006), addiction (Garavan and Hester, 2007) and attention deficit hyperactivity disorder (Crosbie and Schachar, 2001). This has encouraged a drive to further understand the neurochemical substrates of response inhibition. Use of dopamine agonist medication in Parkinson's disease (PD) has been shown to predispose to impulse control disorders (ICDs), manifesting as pathological gambling, hypersexuality and excessive shopping (Weintraub et al., 2015). This observation has therefore prompted investigation of dopamine as a mediator of response

inhibition.

A network involving the basal ganglia, right inferior frontal gyrus and pre-supplementary motor area has been implicated in volitional and habitual inhibition (Jahanshahi et al., 2015), and in mediating stopping on behavioural tasks employed to probe reactive and proactive inhibition (Aron, 2011). Since dopamine is a key neurotransmitter modulating activity in these regions, it seems plausible to study the role of dopamine in response inhibition (Frank, 2005; Pattij and Vanderschuren, 2008). Infusions of a selective D₁ receptor antagonist into the rat striatum improves reactive motor inhibition, whereas infusions of a D₂ receptor antagonist impairs it (Eagle et al., 2011). In humans, positron emission tomography of striatal D₂ and D₃ receptor availability is negatively correlated with the speed of response inhibition and positively correlated with inhibition related functional magnetic resonance imaging activation in the fronto-striatal stopping network (Ghahremani et al., 2012). Administration of the dopamine and noradrenaline reuptake inhibitor, amphetamine, increases D₂ receptor expression and improves measures of reactive inhibition (Hamidovic et al., 2009).

^{*} Corresponding author.

E-mail address: vishal.rawji.11@ucl.ac.uk (V. Rawji).

<https://doi.org/10.1016/j.neuropharm.2020.108278>

Received 26 May 2020; Received in revised form 26 July 2020; Accepted 17 August 2020

Available online 19 August 2020

0028-3908/© 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

In addition to the link between D₁/D₂ receptors, response inhibition and impulsivity (London, 2016), an association between dopamine agonists with D₃ receptor affinity and ICD generation in PD has been found; with pramipexole and ropinirole being two agents both with relatively high D₃ affinity compared to other dopamine agonists and greatest risk of ICD generation (Seeman, 2015; Weiss and Marsh, 2012). The link between use of dopamine agonists with relatively high D₃ affinity and response inhibition remains limited and only reactive inhibition has been explored (Macdonald et al., 2012; Murphy et al., 2017). The effect of these agents on proactive inhibition, on the other hand, has not been investigated.

Our aim was to investigate the effect of dopamine agonists on reactive and proactive response inhibition in healthy participants. We chose the dopamine agonist, ropinirole, which is commonly used clinically and has been implicated in the generation of ICDs in PD. Ropinirole directly activates dopamine receptors with a relatively high affinity for D₃ receptors (Coldwell et al., 1999; Perachon et al., 1999) and hence is a suitable candidate to explore the effect of dopamine agonists on motor inhibition. We devised a randomised, double-blind, placebo-controlled trial to investigate reactive and proactive inhibition in a conditional stop signal task (CSST) under the influence of a placebo or ropinirole.

2. Methods

2.1. Participants

Participants were recruited from the staff and students of University College London. Self-reported questionnaires were used to exclude any participants with psychiatric or neurological illness, drug or alcohol abuse, concurrent medication use and also for any contraindications to ropinirole. The study was approved by ethical approval from the University College London Research Ethics Committee and informed, signed consent was gained in accordance with the Declaration of Helsinki. A power calculation showed that 30 participants would be needed to show a 20% reduction of the response delay effect (RDE), the measure of proactive inhibition, under ropinirole, assuming an intraclass correlation coefficient of 0.655 with 80% power at an alpha level of 0.05. Therefore, 30 healthy volunteers (20 male) aged 19–30 (mean age 23.63, SD 3.64) participated in this within-subject study.

2.2. Conditional stop-signal task (CSST)

The conditional stop-signal task (CSST), shown in Fig. 1, is a validated task to probe reactive and proactive inhibition (Jahfari et al., 2010; Obeso et al., 2014, 2011; Rawji et al., 2020). Participants performed four blocks of the CSST driven by a custom-made MATLAB (MathWorks) script using Psychtoolbox. Each block consisted of 102 go trials (51 critical, 51 non-critical) and 34 stop trials (17 critical and 17 non-critical). A trial on the CSST begins with a white fixation cross, which is replaced 500 ms later by one of two imperative stimuli (right or left arrow). The presentation of these arrows is random, and each occurs with 50% probability. The participant is asked to respond as quickly as possible to the right or left imperative stimulus by pressing the 'M' or 'Z' key on the keyboard with their right or left index fingers, respectively. On 25% of the trials, a stop signal is presented after the go signal, which instructs participants to abort their ongoing movement (stop trial). The timing of this delay between go and stop signals is called the stop signal delay (SSD). The SSD can occur at one of four time points (100, 150, 200 and 250 ms) and was adjusted using a staircase tracking procedure. The SSD for a particular trial was altered based on the outcome of the previous trial; successfully stopping in the previous stop trial would increase SSD by 50 ms (to make the next trial harder to inhibit). Failure to stop on a stop trial would decrease SSD by 50 ms in the next trial (thereby making stopping easier on the next trial). SSD was set to 150 ms at the beginning of each block. Catch trials, where no signals were given, were also presented. At the beginning of each block, participants

were told that they would have to follow the stopping rule if the stop signal was presented for one direction (critical direction) but to ignore the stop signal if it appeared after the other imperative signal (non-critical direction). Hence, responses between the critical and non-critical responses could be compared to determine proactive control. The structure of the block was pseudorandomised, such that one stop trial appears in every four trials.

Reaction times were measured as the time interval between the imperative stimulus (right arrow) onset and the button press. Trials were first organised into whether they were to the critical or non-critical direction. For ease, the remainder of this section will refer to 'right' as the critical direction and left as the non-critical direction. The critical go reaction time was the reaction time measured on critical (right arrow) go trials and the non-critical go reaction time was the reaction time measured during non-critical (left arrow) go trials. $p(\text{inhibit})$ was calculated as the proportion of successful stop trials (where the participant correctly aborted their response) to the critical (right) direction. The reaction time on failed stop trials (stop trials where the participant failed to stop and hence pressed a button) was also calculated (Stop respond reaction time). The stop-signal reaction time (SSRT) was calculated using the integration method (Verbruggen et al., 2013; Verbruggen and Logan, 2009), which integrates the go RT distribution and finds the RT at which the stop process finishes. The stop processes RT is estimated by finding the RT which the integral equals the probability of responding. The integration method ranks Go trials by RT and then finds the n th trial RT, where n represents $p(\text{inhibit}) \times \text{number of Go trials}$. SSRT is then calculated by subtracting the SSD from this n th RT. The number of omitted trials were also recorded – omitted trials were ones where no button press was made. Participants slow down their responses in anticipation of potential stopping – which reflects proactive inhibition. To measure this behaviourally, we calculated the response delay effect (RDE) by subtracting the non-critical (left) go reaction time from the critical (right) go reaction time. Conflict-induced slowing (CIS), a measure of temporary braking to stop signals on non-critical trials, was measured by subtracting the non-critical go reaction time (left go trial) from the non-critical stop reaction time (left stop trial). Importantly, participants were told to prioritise responding to go stimuli and not to slow-down in anticipation of a stop-signal.

2.3. Protocol

The study was approved by the Local Ethics Committee (UCL Ethics ID: 9669/002). Written, informed consent was obtained from each participant. After performing one block of the CSST, as a practice block, participants were then given one of two pills (ropinirole 1 mg or placebo). Both the participants and the experimenter were blinded and only a third-party investigator, not part of the study, knew the identity of the pills. For each participant, the pill given was selected using a random number generator. The participant stayed in the room for 1 h, a time period consistent for ropinirole to reach an appropriate blood level to have CNS effects (Acton and Broom, 1989; Monte-Silva et al., 2009). Following this, the participants performed four blocks of the CSST: two blocks with right as the critical direction and two blocks with left at the critical direction. The order of these blocks was also randomised. After at least 48 h for drug washout, the participant returned to the laboratories and underwent the same protocol as session one, except with the other pill.

2.4. Drift-diffusion modelling

A Bayesian hierarchical drift-diffusion model (HDDM) (Wiecki et al., 2013) was used to investigate the strategic effects on task performance on the go trials of the CSST when stopping may (critical) or may not (non-critical) be required. HDDMs are used to model two-choice, decision-making tasks and aim to resolve the parameters modulated when decisions are made under different circumstances. The model outline is

such that activity starts at a starting point (z). After a delay for sensory processing of the imperative stimulus (n_1), activity increases towards one of two decision boundaries (a , one for each choice) at a rate (v). When activity reaches one of the thresholds, the choice is selected; after another delay for motor execution (n_2), the choice is made. Usually, the delays for sensory processing and motor execution are combined into one non-decision time (n).

We used the HDDM to investigate how ropinirole modulated decision-making parameters during the CSST. Crucially, the HDDM results in better model fits by taking advantage of both the similarity and differences between the participants' performance; individual participant parameters are drawn from a group posterior such that if participants are similar, the variance in the group distribution is small. We used the HDDM toolbox (Wiecki et al., 2013) to estimate DDM parameters. We computed seven different models by varying drift rate, boundary separation and non-decision time between context (critical vs non-critical) and drug (ropinirole vs placebo). The starting point was set to half of the boundary separation since the left/right go cues could appear with equal probability. The optimal model was chosen by using the deviance information criterion (DIC), where a lower DIC indicates a higher likelihood for that model. To maximise available data for the model, we combined all four blocks per drug condition by labelling trials as critical and non-critical, independent of whether they were right or left-handed responses. Markov chain Monte Carlo sampling methods were used to construct the posteriors distribution for parameters (10,000 samples generated, 2000 burn in). To confirm model convergence, we calculated the R-hat (Gelman-Rubin) statistic.

2.5. Data analyses

We were particularly interested in how behavioural inhibition was altered under the influence of the dopamine agonist, ropinirole. To this end, we performed paired t -tests between conditions (ropinirole and placebo) for the following parameters: RDE (proactive inhibition), SSRT (reactive inhibition), CIS, and go discrimination errors. We considered p values of <0.05 as statistically significant.

Using the HDDM allowed for Bayesian analysis of posterior probability distributions for each parameter, between drug (ropinirole vs placebo) and trial type (critical vs non-critical) conditions. Posterior probabilities of greater than 95% were considered significant.

3. Results

3.1. Behavioural measures

Behavioural measurements are shown in Table 1. As expected from the race model, reaction times on failed stop trials (Stop respond) were faster than reaction times on critical go trials for both placebo and ropinirole conditions (placebo: $t = 9.20$, $p < 0.001$, $d = 0.74$, 95% CI [0.21–1.25]; ropinirole: $t = 3.78$, $p = 0.001$, $d = 0.39$, 95% CI [-0.13 – 0.89]). There was also an expected go reaction time difference between critical and non-critical trials measured as RDE due to the anticipation of stopping on critical trials (placebo: $t = 11.00$, $p < 0.001$, $d = 0.99$, 95% CI [0.44–1.51]; ropinirole: $t = 3.78$, $p = 0.001$, $d = 0.87$, 95% CI [0.33–1.39]).

3.2. Ropinirole reduces proactive inhibition and induces more commission errors

We performed a paired t -test between the RDE for placebo and ropinirole and found significantly reduced proactive inhibition on ropinirole ($t = 2.25$, $p = 0.032$, $d = 0.36$, 95% CI [-0.16 – 0.86]). The SSRT is a measure of reactive inhibition; it is the estimated time taken for stopping on presentation of the stop signal. A paired t -test comparing the SSRTs between drug conditions showed that reactive inhibition was unchanged on ropinirole relative to placebo ($t = 0.29$, $p = 0.770$, $d =$

Table 1

Behavioural measurements from the Conditional Stop-signal task performed by participants on placebo and ropinirole. Mean values are accompanied by SD in brackets. Reaction times are given in milliseconds.

Measure	Measure description	Drug	
		Placebo	Ropinirole
Critical direction			
Go	RT to go stimulus in the critical direction	456.94 (73.97)	460.53 (76.30)
p(inhibit)	% correct inhibition	58.08 (15.57)	53.92 (14.47)
Stop Respond	RT on failure to stop trials	406.00 (65.76)	428.65 (71.70)
Omission error	Mean number of omission errors in critical direction	0.30 (0.95)	0.53 (1.11)
Non-critical direction			
Go	RT to go stimulus in the non-critical direction	386.62 (75.35)	402.00 (75.64)
Stop Respond	RT to stop stimulus in the non-critical direction	430.30 (111.48)	444.62 (108.96)
Omission error	Mean number of omission errors in non-critical direction	0.33 (0.76)	0.97 (2.55)
Other variables			
Go error	% of go discrimination errors	0.60 (0.72)	1.06 (1.19)
Stop signal delay	Delay between go and stop signals	188.82 (33.32)	176.34 (32.25)
SSRT	Estimated time take to abort response	276.29 (83.68)	279.81 (75.65)
Response delay effect	(Critical go) - (Non-critical go) RT	70.32 (35.00)	58.53 (30.78)
Conflict-induced slowing	(Non-critical stop) - (Non-critical go) RT	44.81 (47.17)	48.23 (54.04)

0.04, 95% CI [-0.55 – 0.46]). We also found that under the influence of ropinirole, participants made more go discrimination errors than when on placebo ($t = 2.29$, $p = 0.029$, $d = 0.47$, 95% CI [-0.05 – 0.98]). CIS was unchanged on ropinirole compared to placebo ($t = -0.41$, $p = 0.682$, $d = -0.07$, 95% CI [-0.57 – 0.44]).

3.3. On ropinirole, reduced proactive inhibition is due to failure to raise the decision threshold in anticipation of stop trials

Of the seven models we tested, the one with the lowest DIC was a model allowing boundary separation, drift rate and non-decision time to vary (Table 2); parameter estimation therefore comes from this model. To validate the model, we simulated data for each trial type, under each drug condition, using the parameters from the model with the lowest DIC. The model recapitulated both the mean reaction times (critical go placebo: 461.67 ms, non-critical go placebo: 385.48 ms, critical go ropinirole: 468.41 ms, and non-critical go ropinirole: 400.57 ms) and reaction time distributions for each drug/trial permutation, shown in Fig. 2. Fig. 3 shows the posterior parameter estimation for the critical and non-critical Go trials in the ropinirole and placebo conditions. We

Table 2

Deviance information criterion values for each model. The Table shows the DIC value for each model tested. A lower DIC value indicates a greater likelihood for that model. a = boundary separation, v = drift rate, n = non-decision time.

Model	DIC
A	-46135.48
V	-46842.23
N	-45503.35
A,v	-46795.34
A,n	-46178.97
V,n	-46741.94
A,v,n	-47170.71




Fig. 1. The Conditional stop-signal task (CSST).

The different trial types on the CSST with their appropriate responses (critical direction is right). All stimuli stay on the screen until the next stimulus appears. The stop signal delay (SSD) changes between one of four values depending on the performance of the previous critical stop trial.




Fig. 2. Real and HDDM-predicted reaction times.

Plots show critical (red) and non-critical (blue) reaction times organised by quantile, for each drug condition. Circles represent real data points whereas crosses represent simulated data points. Reaction times are simulated using the HDDM model with the lowest DIC value. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)

first looked at the effect of trial type: during critical Go trials, when participants were slowing their responses and hence employing proactive inhibition, boundary separation was greater (posterior probability 100%), drift rate was lower (posterior probability 100%) and non-decision time was shorter (posterior probability 99.96%), compared to non-critical Go trials. Turning our attention to the effect of ropinirole, we found that participants' boundary separation was smaller (posterior probability 100%), drift rate was lower (posterior probability 100%) and non-decision time was smaller (posterior probability 98.66%), compared to when assessed on placebo.

From the behavioural analysis, we saw that the RDE was smaller on ropinirole than on placebo; indicating that participants engaged in less proactive inhibition on ropinirole. To investigate how this could arise, we looked for interaction effects between drug and trial type for each DDM parameter. We found that ropinirole specifically impaired the ability to raise the decision threshold on trials when stopping might be required (posterior probability 98.60%). A significant interaction between drug and trial type was not present for drift rate (posterior probability 85.43%) or non-decision time (posterior probability

48.99%).

4. Discussion

4.1. A single dose of ropinirole reduces/impairs proactive inhibition in healthy participants

We present data showing how proactive and reactive inhibition are modulated after administration of a single dose of ropinirole, a dopamine agonist with relatively high D_3 affinity. The data show that proactive inhibition is reduced with administration of ropinirole, indexed by a significant decrease in the RDE. This was accompanied by an increase in the number of go discrimination errors on ropinirole relative to placebo. This is a rather surprising finding since the imperative stimuli are unambiguous, but consistent with a previous report that dopamine replacement in PD resulted in more perceptual decision-making errors on a random motion dots task (Huang et al., 2015). By contrast, reactive inhibition as measured by the SSRT, was unaffected by ropinirole administration.

Traditionally, observational and correlative studies have indicated a role of dopamine in response inhibition. Patients with PD (acting as a proxy for chronic dopamine deficiency) show impairments in a variety of tasks probing response inhibition (Obeso et al., 2011), although proactive inhibition seems unaltered in untreated patients (Obeso et al., 2014). Functional neuroimaging studies show an inverse relationship between dopamine receptor (D_1 and D_2) availability and response inhibition (Ghahremani et al., 2012; Lorenz et al., 2015; Robertson et al., 2015; Roessner et al., 2008). Interventional studies have shown similar results, with dopaminergic antagonism using haloperidol, resulting in impaired reactive inhibition (Logemann et al., 2017) and dopaminergic agonism using cabergoline or methylphenidate, resulting in improved reactive inhibition (Nandam et al., 2013, 2011).

A role of ropinirole in response inhibition has been previously explored in healthy adults. In that study, participants were randomised to receive a placebo, 0.5 mg or 1 mg of ropinirole and asked to perform two tasks of response inhibition: a the stop signal task to measure reactive inhibition and a balloon analogue risk task, measuring decisional inhibition, which could be regarded as a form of proactive inhibition. Interestingly, this group also genotyped their participants to derive a dopamine genetic risk score (made up of $DRD1$, $DRD2$, $DRD3$, DAT and $COMT$ polymorphisms), which indexed basal dopamine neurotransmission. They found that ropinirole modulated both forms of inhibition depending on individuals' genetic risk score and concluded, as have others (Congdon et al., 2009; Farrell et al., 2012), that dopamine follows an inverted-U shape dose-response relationship with regard to response inhibition (Macdonald et al., 2012). Whilst we did not measure our participants' dopamine genetic risk score, our results on motor, rather than decisional inhibition reinforce the finding that dopamine agonists modulate proactive response inhibition. It may be the case the underlying genetic susceptibility determines the risk of impulsivity in PD. Indeed, the predictability of ICD generation in PD patients on dopamine replacement is increased when genes associated with ICDs are included in the prediction model (Kraemmer et al., 2016).

Although the aforementioned studies have informed the role of dopamine in reactive inhibition, the literature concerning dopamine and proactive inhibition remains scarce. D_1 and D_2 gene polymorphisms have been shown to predict engagement of proactive inhibition (measured as post-error slowing in a go/no-go task), such that increased D_1 and decreased D_2 receptor expression are associated with increased proactive inhibition (Beu et al., 2019). Given that ropinirole has a relatively high affinity for D_3 receptors, our work extends the mediators of proactive inhibition to include D_3 receptors, as well.




Fig. 3. Drift-diffusion model parameters when participants were on ropinirole or placebo, during critical and non-critical Go trials.

Posterior probability distributions are plotted for drug (ropinirole), trial type (non-critical) and an interaction between the two. The blue, vertical line represents the no-effect value. Statistical significance is confirmed if >95% of the distribution lies outside of this line. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)

4.2. Ropinirole resulted in less context-specific modulation of boundary separation

We investigated the strategy that participants employed when stopping might be required. Under both ropinirole and placebo, our participants decreased their non-decision time, reduced their drift rate and increased their boundary separation on trials when stopping might be required, the latter confirming previous literature (Obeso et al., 2014). We then asked what specific effects ropinirole administration had on changes in strategy when stopping might be required. We found that ropinirole resulted in less context-specific adjustment of the boundary separation when stopping was potentially required on critical trials. This finding was in keeping with the behavioural results, where a significantly smaller RDE and a greater number of commission errors were observed. Interestingly, our results mirror those found by Obeso et al. in patients with PD having undergone therapeutic unilateral subthalamotomy. They used the CSST to investigate proactive and reactive inhibition, and found impaired RDE coupled with a failure to engage in context-dependent adjustment of boundary separation during critical trials after right-sided subthalamotomy (Obeso et al., 2014).

Modulation of the dopaminergic system has been shown to alter strategy used during decision-making. Beste and co-workers used methylphenidate, a dopamine/noradrenaline reuptake inhibitor, to study perceptual decision making in healthy individuals using the random motion dots task. They found that administration of methylphenidate significantly increased drift rates compared to placebo and showed that modulation of the dopaminergic system can selectively modulate evidence accumulation (Beste et al., 2018). Polymorphisms in dopamine genes have been related to the strategy used during a selective stop signal task (Rincón-Pérez et al., 2020). Hence, in addition to acting as a mediator of reactive inhibition, it seems that dopamine has a role in setting the proactive strategy used during specific tasks.

The speed-accuracy tradeoff is a feature of decision-making, whereby decisions that are made faster suffer from decreased accuracy, whereas those that are more accurate are generally slower. The mechanisms by which this tradeoff occurs have been explained using

DDMs, with increases in boundary separation resulting in greater accuracy and slower reaction times (Georgiev et al., 2016). Given that dopamine has a role in response initiation (Klaus et al., 2019) as well as response inhibition, the increase in errors under ropinirole may be due to either a decrease in response inhibition or an increase in the vigour of response initiation. Our results suggest the errors seen under ropinirole are not due to an increase in response initiation, given that drift rate was lower in the ropinirole condition and reaction times were comparable between drug conditions. Instead, the reduction in context-specific modulation of boundary separation implies that impaired response inhibition drives the increase in errors under ropinirole.

Winkel and colleagues have investigated the role of a dopamine agonist, bromocriptine, on the speed-accuracy tradeoff using the random motion dots task. They failed to find an effect of bromocriptine on boundary separation in mediating the tradeoff (Winkel et al., 2012). Crucially, the dopamine receptor affinity profile of bromocriptine differs from that of ropinirole; whilst both agents have a high affinity for D₂ receptors, ropinirole has a relatively higher affinity for D₃ receptors than bromocriptine, and ropinirole has a higher affinity for D₃ receptors than D₂ receptors (Coldwell et al., 1999). Furthermore, the pharmacokinetic profiles of ropinirole and bromocriptine on dopamine receptors also differs, such that bromocriptine has a significantly slower onset of action than ropinirole (Coldwell et al., 1999). The random motion dots task primarily alters decision-making via changes in drift rate via manipulation of motion coherence of the dots, whereas in the CSST, proactive inhibition is modulated by a combination of strategies. It may be the case that dopamine does indeed have the potential to mediate the speed-accuracy tradeoff via D₃ receptors. These studies and our own highlight that the role of dopamine in perceptual decision-making is complex, with interactions between neurotransmitter/receptor specificity and design of behavioural tasks.

4.3. Limitations

We are aware that a multitude of factors, such as BMI or smoking status, affect drug pharmacokinetics and pharmacodynamics. Despite

going unmeasured, these confounds are limited by a within-subject design. Although ropinirole has a relatively high affinity for D₃ receptors, we are aware that it acts on the family of D₂-like receptors, which include D₂, D₃ and D₄ receptors (Kaye and Nicholls, 2000). Therefore, we are unable to pinpoint the effects of ropinirole on proactive inhibition specifically on D₃ receptor activity. Whether our findings can be generalized to all dopamine agonists remains to be established; the effect observed in this study may be specific to ropinirole. Future studies could therefore aim to explore a number of dopamine agonists with varying D₃ receptor activity. If causative, then deficits in proactive inhibition should scale with dopamine agonist D₃ receptor affinity.

Whilst we have drawn parallels between our findings and impulsivity in PD, we note two important caveats; our participants have a preserved dopaminergic state, whereas patients with PD have variable dopaminergic denervation in motor and limbic regions. Furthermore, the doses received by patients with PD typically exceed those used in this study. In view of these differences, conclusions of acute dopaminergic administration in healthy populations cannot be extrapolated to patients with PD. Although response inhibition is impaired in PD patients irrespective of dopaminergic medication load (Obeso et al., 2011), the specific effect of dopamine agonists on response inhibition has not been investigated in patients with PD. The study by Obeso and colleagues used the levodopa-equivalent daily dose (LEDD) as the metric to measure dopaminergic medication load. However, LEDDs combine all medications used for PD and hence the specific role of dopaminergic agonists is not isolated. Given that dopamine agonists specifically confer an increased risk of ICDs (Voon et al., 2017, 2011; Weintraub et al., 2015) we encourage specific investigation into the role of dopamine agonists in PD by measuring response inhibition in patients on and off dopamine agonist medications or between groups of patients who take dopamine agonists against those who do not. Furthermore, the generation of ICDs may have multiple components such as delay aversion, an inability to take time to reflect/weigh evidence or delay gratification, and motor inhibition. The former two components are measured using delay discounting and probabilistic learning tasks while motor inhibition is studied using the CSST. In view of this multifactorial nature of ICDs, future studies should seek to investigate other models of impulsivity.

5. Conclusions

Our results from a placebo controlled, double-blind study provide novel evidence that an acute dose of ropinirole selectively reduces proactive inhibition in healthy participants. The results of the HDDM further indicate that ropinirole results in less context-specific adjustment of the boundary separation when stopping is potentially required. These results may have implications for the potential of this dopamine agonist with high D₃ affinity to induce impulse control disorders in susceptible patients with Parkinson's disease.

Funding and disclosures

This study was funded by doctoral training grant MR/K501268/1 from the Medical Research Council UK. The authors have nothing to disclose.

CRediT authorship contribution statement

Vishal Rawji: collected and analysed data, contributed in the design of the study, involved in the drafting and revisions of the manuscript, approved this manuscript. **Lorenzo Rocchi**: involved in the drafting and revisions of the manuscript, contributed in the design of the study, approved this manuscript. **Tom Foltynie**: involved in the drafting and revisions of the manuscript, contributed in the design of the study, provided the ropinirole and placebo used in the study, approved this manuscript. **John C. Rothwell**: involved in the drafting and revisions of

the manuscript, contributed in the design of the study, approved this manuscript. **Marjan Jahanshahi**: involved in the drafting and revisions of the manuscript, contributed in the design of the study, approved this manuscript.

Acknowledgements

We would like to thank all participants who gave up their time to take part in this study. VR would like to thank Miss Catherine Storm for her support during the writing of this manuscript.

References

- Acton, G., Broom, C., 1989. A dose rising study of the safety and effects on serum prolactin of SK&F 101468, a novel dopamine D₂-receptor agonist. *Br. J. Clin. Pharmacol.* 28, 435–441. <https://doi.org/10.1111/j.1365-2125.1989.tb03524.x>.
- Aron, A.R., 2011. From reactive to proactive and selective control: developing a richer model for stopping inappropriate responses. *Biol. Psychiatr.* 69 <https://doi.org/10.1016/j.biopsych.2010.07.024> e55–e68.
- Bellgrove, M.A., Chambers, C.D., Vance, A., Hall, N., Karamitsos, M., Bradshaw, J.L., 2006. Lateralized deficit of response inhibition in early-onset schizophrenia. *Psychol. Med.* 36, 495–505. <https://doi.org/10.1017/S0033291705006409>.
- Beste, C., Adelhöfer, N., Gohil, K., Passow, S., Roessner, V., Li, S.C., 2018. Dopamine modulates the efficiency of sensory evidence accumulation during perceptual decision making. *Int. J. Neuropsychopharmacol.* 21, 649–655. <https://doi.org/10.1093/ijnp/pyy019>.
- Beu, N.D., Burns, N.R., Baetu, I., 2019. Polymorphisms in dopaminergic genes predict proactive response inhibition. *Eur. J. Neurosci.* 49, 1127–1148. <https://doi.org/10.1111/ejn.14323>.
- Coldwell, M.C., Boyfield, I., Brown, T., Hagan, J.J., Middlemiss, D.N., 1999. Comparison of the functional potencies of ropinirole and other dopamine receptor agonists at human D(2(long)), D3and D4.4receptors expressed in Chinese hamster ovary cells. *Br. J. Pharmacol.* 127, 1696–1702. <https://doi.org/10.1038/sj.bjp.0702673>.
- Congdon, E., Constable, R.T., Lesch, K.P., Canli, T., 2009. Influence of SLC6A3 and COMT variation on neural activation during response inhibition. *Biol. Psychol.* 81, 144–152. <https://doi.org/10.1016/j.biopsycho.2009.03.005>.
- Crosbie, J., Schachar, R., 2001. Deficient inhibition as a marker for familial ADHD. *Am. J. Psychiatr.* 158, 1884–1890. <https://doi.org/10.1176/appi.ajp.158.11.1884>.
- Eagle, D.M., Wong, J.C.K., Allan, M.E., Mar, A.C., Theobald, D.E., Robbins, T.W., 2011. Contrasting roles for dopamine D1 and D2 receptor subtypes in the dorsomedial striatum but not the nucleus accumbens core during behavioral inhibition in the stop-signal task in rats. *J. Neurosci.* 31, 7349–7356. <https://doi.org/10.1523/JNEUROSCI.6182-10.2011>.
- Farrell, S.M., Tunbridge, E.M., Braeutigam, S., Harrison, P.J., 2012. COMT Val158met genotype determines the direction of cognitive effects produced by catechol-O-methyltransferase inhibition. *Biol. Psychiatr.* 71, 538–544. <https://doi.org/10.1016/j.biopsych.2011.12.023>.
- Frank, M.J., 2005. Dynamic dopamine modulation in the basal ganglia: a neurocomputational account of cognitive deficits in medicated and nonmedicated Parkinsonism. *J. Cognit. Neurosci.* 17, 51–72. <https://doi.org/10.1162/0898929052880093>.
- Garavan, H., Hester, R., 2007. The role of cognitive control in cocaine dependence. *Neuropsychol. Rev.* 17, 337–345. <https://doi.org/10.1007/s11065-007-9034-x>.
- Georgiev, D., Rocchi, L., Tocco, P., Speekenbrink, M., Rothwell, J.C., Jahanshahi, M., 2016. Continuous theta burst stimulation over the dorsolateral prefrontal cortex and the pre-SMA alter drift rate and response thresholds respectively during perceptual decision-making. *Brain Stimulation* 9, 601–608. <https://doi.org/10.1016/j.brs.2016.04.004>.
- Gahremani, D.G., Lee, B., Robertson, C.L., Tabibnia, G., Morgan, A.T., De Shetler, N., Brown, A.K., Monterosso, J.R., Aron, A.R., Mandelkern, M.A., Poldrack, R.A., London, E.D., 2012. Striatal dopamine D₂/D₃ receptors mediate response inhibition and related activity in frontostriatal neural circuitry in humans. *J. Neurosci.: Off. J. Soc. Neurosci.* 32, 7316–7324. <https://doi.org/10.1523/JNEUROSCI.4284-11.2012>.
- Hamidovic, A., Dlugos, A., Skol, A., Palmer, A.A., Wit, H.de, 2009. Evaluation of genetic variability in the dopamine receptor D2 in relation to behavioral inhibition and impulsivity/sensation seeking: an exploratory study with d-amphetamine in healthy participants. *Exp. Clin. Psychopharmacol.* 17, 374–383. <https://doi.org/10.1037/a0017840>.
- Huang, Y.T., Georgiev, D., Foltynie, T., Limousin, P., Speekenbrink, M., Jahanshahi, M., 2015. Different effects of dopaminergic medication on perceptual decision-making in Parkinson's disease as a function of task difficulty and speed-accuracy instructions. *Neuropsychologia* 75, 577–587. <https://doi.org/10.1016/j.neuropsychologia.2015.07.012>.
- Jahanshahi, M., Obeso, I., Rothwell, J.C., Obeso, J.A., 2015. A fronto-striato-subthalamic-pallidal network for goal-directed and habitual inhibition. *Nat. Rev. Neurosci.* 16, 719–732. <https://doi.org/10.1038/nrn4038>.
- Jahfari, S., Stinear, C.M., Claffey, M., Verbruggen, F., Aron, A.R., 2010. Responding with restraint: what are the neurocognitive mechanisms? *J. Cognit. Neurosci.* 22, 1479–1492. <https://doi.org/10.1162/jocn.2009.21307>.
- Kaye, C.M., Nicholls, B., 2000. Clinical pharmacokinetics of ropinirole. *Clin. Pharmacokinet.* 39, 243–254. <https://doi.org/10.2165/00003088-200039040-00001>.

- Klaus, A., Alves da Silva, J., Costa, R.M., 2019. What, if, and when to move: basal ganglia circuits and self-paced action initiation. *Annu. Rev. Neurosci.* 42, 459–483. <https://doi.org/10.1146/annurev-neuro-072116-031033>.
- Kraemmer, J., Smith, K., Weintraub, D., Guillemot, V., Nalls, M.A., Cormier-Dequaire, F., Moszer, I., Brice, A., Singleton, A.B., Corvol, J.C., 2016. Clinical-genetic model predicts incident impulse control disorders in Parkinson's disease. *J. Neurol. Neurosurg. Psychiatr.* 87, 1106–1111. <https://doi.org/10.1136/jnnp-2015-312848>.
- Logemann, H.N.A., Böcker, K.B.E., Deschamps, P.K.H., van Harten, P.N., Koning, J., Kemner, C., Logemann-Molnár, Z., Kenemans, J.L., 2017. Haloperidol 2 mg impairs inhibition but not visuospatial attention. *Psychopharmacology* 234, 235–244. <https://doi.org/10.1007/s00213-016-4454-z>.
- London, E.D., 2016. Impulsivity, Stimulant Abuse, and Dopamine Receptor Signaling. In: *Advances in Pharmacology*, first ed. Elsevier Inc. <https://doi.org/10.1016/bs.apha.2016.01.002>.
- Lorenz, R.C., Gleich, T., Buchert, R., Schlagenhaut, F., Kühn, S., Gallinat, J., 2015. Interactions between glutamate, dopamine, and the neuronal signature of response inhibition in the human striatum. *Hum. Brain Mapp.* 36, 4031–4040. <https://doi.org/10.1002/hbm.22895>.
- Macdonald, H.J., Stinear, C.M., Ren, A., Coxon, J.P., Kao, J., Macdonald, L., Snow, B., Cramer, S.C., Byblow, W.D., 2012. Dopamine gene profiling to predict impulse control and effects of dopamine agonist ropinirole. *J. Cognit. Neurosci.* 10, 909–919. https://doi.org/10.1162/jocn_a_00946.
- Monte-Silva, K., Kuo, M.-F., Thirugnanasambandam, N., Liebetanz, D., Paulus, W., Nitsche, M.A., 2009. Dose-dependent inverted U-shaped effect of dopamine (D2-Like) receptor activation on focal and nonfocal plasticity in humans. *J. Neurosci.* 29, 6124–6131. <https://doi.org/10.1523/JNEUROSCI.0728-09.2009>.
- Murphy, A., Nestor, L.J., McGonigle, J., Paterson, L., Boyapati, V., Ersche, K.D., Flechais, R., Kuchibatla, S., Metastasio, A., Orban, C., Passetti, F., Reed, L., Smith, D., Suckling, J., Taylor, E., Robbins, T.W., Lingford-Hughes, A., Nutt, D.J., Deakin, J.F.W., Elliott, R., 2017. Acute D3 antagonist GSK598809 selectively enhances neural response during monetary reward anticipation in drug and alcohol dependence. *Neuropsychopharmacology* 42, 1049–1057. <https://doi.org/10.1038/npp.2016.289>.
- Nandam, L.S., Hester, R., Wagner, J., Cummins, T.D.R., Garner, K., Dean, A.J., Kim, B.N., Nathan, P.J., Mattingley, J.B., Bellgrove, M.A., 2011. Methylphenidate but not atomoxetine or citalopram modulates inhibitory control and response time variability. *Biol. Psychiatr.* 69, 902–904. <https://doi.org/10.1016/j.biopsych.2010.11.014>.
- Nandam, L.S., Hester, R., Wagner, J., Dean, A.J., Messer, C., Honeysett, A., Nathan, P.J., Bellgrove, M.A., 2013. Dopamine D2 receptor modulation of human response inhibition and error awareness. *J. Cognit. Neurosci.* 25, 649–656. https://doi.org/10.1162/jocn_a_00327.
- Obeso, I., Wilkinson, L., Casabona, E., Bringas, M.L., Álvarez, M., Álvarez, L., Pavón, N., Rodríguez-Oroz, M.C., Macías, R., Obeso, J.A., Jahanshahi, M., 2011. Deficits in inhibitory control and conflict resolution on cognitive and motor tasks in Parkinson's disease. *Exp. Brain Res.* 212, 371–384. <https://doi.org/10.1007/s00221-011-2736-6>.
- Obeso, I., Wilkinson, L., Casabona, E., Speekenbrink, M., Bringas, M.L., Álvarez, M., Álvarez, L., Pavón, N., Rodríguez-Oroz, M.C., Macías, R., Obeso, J.A., Jahanshahi, M., 2014. The subthalamic nucleus and inhibitory control: impact of subthalamotomy in Parkinson's disease. *Brain* 137, 1470–1480. <https://doi.org/10.1093/brain/awu058>.
- Pattij, T., Vanderschuren, L.J.M.J., 2008. The neuropharmacology of impulsive behaviour. *Trends Pharmacol. Sci.* 29, 192–199. <https://doi.org/10.1016/j.tips.2008.01.002>.
- Perachon, S., Schwartz, J.C., Sokoloff, P., 1999. Functional potencies of new antiparkinsonian drugs at recombinant human dopamine D1, D2 and D3 receptors. *Eur. J. Pharmacol.* 366, 293–300. [https://doi.org/10.1016/S0014-2999\(98\)00896-6](https://doi.org/10.1016/S0014-2999(98)00896-6).
- Rawji, V., Modi, S., Latorre, A., Rocchi, L., Hockey, L., Bhatia, K., Joyce, E., Rothwell, J.C., Jahanshahi, M., 2020. Impaired automatic but intact volitional inhibition in primary tic disorders. *Brain: J. Neurol.* 143, 906–919. <https://doi.org/10.1093/brain/awaa024>.
- Rincón-Pérez, I., Echeverry-Alzate, V., Sánchez-Carmona, A.J., Bühler, K.M., Hinojosa, J.A., López-Moreno, J.A., Albert, J., 2020. The influence of dopaminergic polymorphisms on selective stopping. *Behav. Brain Res.* 381, 112441. <https://doi.org/10.1016/j.bbr.2019.112441>.
- Robertson, C.L., Ishibashi, K., Mandelkern, M.A., Brown, A.K., Ghahremani, D.G., Sabb, F., Bilder, R., Cannon, T., Borg, J., London, E.D., 2015. Striatal D1- and D2-type dopamine receptors are linked to motor response inhibition in human subjects. *J. Neurosci.* 35, 5990–5997. <https://doi.org/10.1523/JNEUROSCI.4850-14.2015>.
- Roessner, V., Albrecht, B., Dechent, P., Baudewig, J., Rothenberger, A., 2008. Normal response inhibition in boys with Tourette syndrome. *Behav. Brain Funct.* 4, 1–6. <https://doi.org/10.1186/1744-9081-4-29>.
- Seeman, P., 2015. Parkinson's disease treatment may cause impulse-control disorder via dopamine D3 receptors. *Synapse* 69, 183–189. <https://doi.org/10.1002/syn.21805>.
- Verbruggen, F., Chambers, C.D., Logan, G.D., 2013. Fictitious inhibitory differences: how skewness and slowing distort the estimation of stopping latencies. *Psychol. Sci.* 24, 352–362. <https://doi.org/10.1177/0956797612457390>.
- Verbruggen, F., Logan, G.D., 2009. Models of response inhibition in the stop-signal and stop-change paradigms. *Neurosci. Biobehav. Rev.* 33, 647–661. <https://doi.org/10.1016/j.neubiorev.2008.08.014>.
- Voon, V., Gao, J., Brezing, C., Symmonds, M., Ekanayake, V., Fernandez, H., Dolan, R.J., Hallett, M., 2011. Dopamine agonists and risk: impulse control disorders in Parkinson's; Disease. *Brain* 134, 1438–1446. <https://doi.org/10.1093/brain/awr080>.
- Voon, V., Napier, T.C., Frank, M.J., Sgambato-Faure, V., Grace, A.A., Rodriguez-Oroz, M., Obeso, J., Bezdard, E., Fernagut, P.O., 2017. Impulse control disorders and levodopa-induced dyskinesias in Parkinson's disease: an update. *Lancet Neurol.* 16, 238–250. [https://doi.org/10.1016/S1474-4422\(17\)30004-2](https://doi.org/10.1016/S1474-4422(17)30004-2).
- Weintraub, D., David, A.S., Evans, A.H., Grant, J.E., Stacy, M., 2015. Clinical spectrum of impulse control disorders in Parkinson's disease. *Mov. Disord.* 30, 121–127. <https://doi.org/10.1002/mds.26016>.
- Weiss, H.D., Marsh, L., 2012. Impulse control disorders and compulsive behaviors associated with dopaminergic therapies in Parkinson disease. *Neurology: Clin. Pract.* 2, 267–274. <https://doi.org/10.1212/CPJ.0b013e318278be9b>.
- Wiecki, T.V., Sofer, I., Frank, M.J., 2013. HDDM: hierarchical bayesian estimation of the drift-diffusion model in Python. *Front. Neuroinf.* 7, 1–10. <https://doi.org/10.3389/fninf.2013.00014>.
- Winkel, J., van Maanen, L., Ratcliff, R., Van der Schaaf, M.E., Van Schouwenburg, M.R., Cools, R., Forstmann, B.U., 2012. Bromocriptine does not alter speed-accuracy tradeoff. *Front. Neurosci.* 6, 1–8. <https://doi.org/10.3389/fnins.2012.00126>.